_id
6919e27d3c536f8df2317fb1
Ticker
0RIM.LSE
Name
GenSight Biologics S.A.
Exchange
LSE
Address
74, rue du Faubourg Saint-Antoine, Paris, France, 75012
Country
UK
Sector
Industry
Currency
EUR
Website
https://www.gensight-biologics.com
Description
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa and dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Française contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies. The company was incorporated in 2012 and is headquartered in Paris, France.
Last Close
0.1062
Volume
8630
Current Price
0.1044
Change
-4.519774011299433
Last Updated
2025-12-29T14:48:36.194Z
Image
https://logo.clearbit.com/www.gensight-biologics.com
Ipo Date
-
Market Cap
2873490
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2023-06-30
Revenue
-
Cost Of Revenue
-
Gross Profit
-
Operating Expenses
-
Operating Income
-
Interest Expense
-
Pretax Income
-
Net Income
-
Eps
-
Dividends Per Share
-
Shares Outstanding
24375000
Income Tax Expense
1000
EBITDA
-
Operating Margin
-
Total Other Income Expense Net
-
Cash
-
Short Term Investments
-
Receivables
5045000
Inventories
-
Total Current Assets
14552000
Property Plant Equipment
1546000
Total Assets
-
Payables
11315000
Short Term Debt
-
Long Term Debt
-
Total Liabilities
30584000
Equity
-
Bs_currency_symbol
EUR
Depreciation
329000
Change In Working Capital
-
Cash From Operations
-8104000
Capital Expenditures
0
Cash From Investing
76500
Cash From Financing
3204000
Net Change In Cash
-4794500
Cf_currency_symbol
EUR
PE
-
PB
-
ROE
-
ROA
-
FCF
-8104000
Fcf Percent
-
Piotroski FScore
0
Health Score
45
Deep Value Investing Score
0
Defensive Investing Score
4
Dividend Investing Score
1.5
Economic Moat Investing Score
1
Garp Investing Score
0
Growth Investing Score
0
Momentum Investing Score
3.5
Net Net Investing Score
0
Quality Investing Score
0
Value Investing Score
0.5
Quarters > 0 > quarter
2023-06-30
Quarters > 0 > income Statement > revenue
-
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
-
Quarters > 0 > income Statement > operating Expenses
-
Quarters > 0 > income Statement > operating Income
-
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-
Quarters > 0 > income Statement > net Income
-
Quarters > 0 > income Statement > eps
-
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
-
Quarters > 0 > income Statement > income Tax Expense
1000
Quarters > 0 > income Statement > EBITDA
-
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
-
Quarters > 0 > income Statement > currency_symbol
EUR
Quarters > 0 > balance Sheet > cash
-
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
5045000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
14552000
Quarters > 0 > balance Sheet > property Plant Equipment
1546000
Quarters > 0 > balance Sheet > total Assets
-
Quarters > 0 > balance Sheet > payables
11315000
Quarters > 0 > balance Sheet > short Term Debt
-
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
30584000
Quarters > 0 > balance Sheet > equity
-
Quarters > 0 > balance Sheet > currency_symbol
EUR
Quarters > 0 > cash Flow > net Income
-5981000
Quarters > 0 > cash Flow > depreciation
329000
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
-8104000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
76500
Quarters > 0 > cash Flow > cash From Financing
3204000
Quarters > 0 > cash Flow > net Change In Cash
-4794500
Quarters > 0 > cash Flow > currency_symbol
EUR
Quarters > 0 > ratios > PE
-
Quarters > 0 > ratios > PB
-
Quarters > 0 > ratios > ROE
-
Quarters > 0 > ratios > ROA
-
Quarters > 0 > ratios > FCF
-8104000
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
45
Quarters > 1 > quarter
2023-03-31
Quarters > 1 > income Statement > revenue
-
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
-
Quarters > 1 > income Statement > operating Income
-
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-
Quarters > 1 > income Statement > net Income
-
Quarters > 1 > income Statement > eps
-
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
-
Quarters > 1 > income Statement > income Tax Expense
1000
Quarters > 1 > income Statement > EBITDA
-
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-
Quarters > 1 > income Statement > currency_symbol
EUR
Quarters > 1 > balance Sheet > cash
-
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
5045000
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
14552000
Quarters > 1 > balance Sheet > property Plant Equipment
1546000
Quarters > 1 > balance Sheet > total Assets
-
Quarters > 1 > balance Sheet > payables
11315000
Quarters > 1 > balance Sheet > short Term Debt
-
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
30584000
Quarters > 1 > balance Sheet > equity
-
Quarters > 1 > balance Sheet > currency_symbol
EUR
Quarters > 1 > cash Flow > net Income
-5981000
Quarters > 1 > cash Flow > depreciation
329000
Quarters > 1 > cash Flow > change In Working Capital
-
Quarters > 1 > cash Flow > cash From Operations
-8104000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
76500
Quarters > 1 > cash Flow > cash From Financing
3204000
Quarters > 1 > cash Flow > net Change In Cash
-4794500
Quarters > 1 > cash Flow > currency_symbol
EUR
Quarters > 1 > ratios > PE
-
Quarters > 1 > ratios > PB
-
Quarters > 1 > ratios > ROE
-
Quarters > 1 > ratios > ROA
-
Quarters > 1 > ratios > FCF
-8104000
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
45
Quarters > 2 > quarter
2022-12-31
Quarters > 2 > income Statement > revenue
-
Quarters > 2 > income Statement > cost Of Revenue
-
Quarters > 2 > income Statement > gross Profit
-
Quarters > 2 > income Statement > operating Expenses
-
Quarters > 2 > income Statement > operating Income
-
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-
Quarters > 2 > income Statement > net Income
-
Quarters > 2 > income Statement > eps
-
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
-
Quarters > 2 > income Statement > income Tax Expense
2000
Quarters > 2 > income Statement > EBITDA
-
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
-
Quarters > 2 > income Statement > currency_symbol
EUR
Quarters > 2 > balance Sheet > cash
-
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
3490000
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
22947000
Quarters > 2 > balance Sheet > property Plant Equipment
2268000
Quarters > 2 > balance Sheet > total Assets
-
Quarters > 2 > balance Sheet > payables
7813000
Quarters > 2 > balance Sheet > short Term Debt
-
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
14642000
Quarters > 2 > balance Sheet > equity
-
Quarters > 2 > balance Sheet > currency_symbol
EUR
Quarters > 2 > cash Flow > net Income
-8455500
Quarters > 2 > cash Flow > depreciation
257500
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
-8533000
Quarters > 2 > cash Flow > capital Expenditures
51500
Quarters > 2 > cash Flow > cash From Investing
39500
Quarters > 2 > cash Flow > cash From Financing
1678500
Quarters > 2 > cash Flow > net Change In Cash
-6768500
Quarters > 2 > cash Flow > currency_symbol
EUR
Quarters > 2 > ratios > PE
-
Quarters > 2 > ratios > PB
-
Quarters > 2 > ratios > ROE
-
Quarters > 2 > ratios > ROA
-
Quarters > 2 > ratios > FCF
-8584500
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
45
Quarters > 3 > quarter
2022-09-30
Quarters > 3 > income Statement > revenue
-
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
-
Quarters > 3 > income Statement > operating Expenses
-
Quarters > 3 > income Statement > operating Income
-
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-
Quarters > 3 > income Statement > net Income
-
Quarters > 3 > income Statement > eps
-
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
-
Quarters > 3 > income Statement > income Tax Expense
2000
Quarters > 3 > income Statement > EBITDA
-
Quarters > 3 > income Statement > operating Margin
-
Quarters > 3 > income Statement > total Other Income Expense Net
-
Quarters > 3 > income Statement > currency_symbol
EUR
Quarters > 3 > balance Sheet > cash
-
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
3490000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
22947000
Quarters > 3 > balance Sheet > property Plant Equipment
2268000
Quarters > 3 > balance Sheet > total Assets
-
Quarters > 3 > balance Sheet > payables
7813000
Quarters > 3 > balance Sheet > short Term Debt
-
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
14642000
Quarters > 3 > balance Sheet > equity
-
Quarters > 3 > balance Sheet > currency_symbol
EUR
Quarters > 3 > cash Flow > net Income
-8455500
Quarters > 3 > cash Flow > depreciation
257500
Quarters > 3 > cash Flow > change In Working Capital
-
Quarters > 3 > cash Flow > cash From Operations
-8533000
Quarters > 3 > cash Flow > capital Expenditures
51500
Quarters > 3 > cash Flow > cash From Investing
39500
Quarters > 3 > cash Flow > cash From Financing
1678500
Quarters > 3 > cash Flow > net Change In Cash
-6768500
Quarters > 3 > cash Flow > currency_symbol
EUR
Quarters > 3 > ratios > PE
-
Quarters > 3 > ratios > PB
-
Quarters > 3 > ratios > ROE
-
Quarters > 3 > ratios > ROA
-
Quarters > 3 > ratios > FCF
-8584500
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-
Quarters > 3 > health Score
45
Annuals > 0 > quarter
2022-12-31
Annuals > 0 > income Statement > revenue
-
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
-
Annuals > 0 > income Statement > operating Expenses
-
Annuals > 0 > income Statement > operating Income
-
Annuals > 0 > income Statement > interest Expense
-
Annuals > 0 > income Statement > pretax Income
-
Annuals > 0 > income Statement > net Income
-
Annuals > 0 > income Statement > eps
-
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
-
Annuals > 0 > income Statement > income Tax Expense
5000
Annuals > 0 > income Statement > EBITDA
-
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-
Annuals > 0 > income Statement > currency_symbol
EUR
Annuals > 0 > balance Sheet > cash
-
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
3490000
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
22947000
Annuals > 0 > balance Sheet > property Plant Equipment
2268000
Annuals > 0 > balance Sheet > total Assets
-
Annuals > 0 > balance Sheet > payables
7813000
Annuals > 0 > balance Sheet > short Term Debt
-
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
14642000
Annuals > 0 > balance Sheet > equity
-
Annuals > 0 > balance Sheet > currency_symbol
EUR
Annuals > 0 > cash Flow > net Income
-27600000
Annuals > 0 > cash Flow > depreciation
1061000
Annuals > 0 > cash Flow > change In Working Capital
-
Annuals > 0 > cash Flow > cash From Operations
-33753000
Annuals > 0 > cash Flow > capital Expenditures
252000
Annuals > 0 > cash Flow > cash From Investing
172000
Annuals > 0 > cash Flow > cash From Financing
95000
Annuals > 0 > cash Flow > net Change In Cash
-33679000
Annuals > 0 > cash Flow > currency_symbol
EUR
Annuals > 0 > ratios > PE
-
Annuals > 0 > ratios > PB
-
Annuals > 0 > ratios > ROE
-
Annuals > 0 > ratios > ROA
-
Annuals > 0 > ratios > FCF
-34005000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
45
Annuals > 1 > quarter
2021-12-31
Annuals > 1 > income Statement > revenue
-
Annuals > 1 > income Statement > cost Of Revenue
-
Annuals > 1 > income Statement > gross Profit
-
Annuals > 1 > income Statement > operating Expenses
-
Annuals > 1 > income Statement > operating Income
-
Annuals > 1 > income Statement > interest Expense
0
Annuals > 1 > income Statement > pretax Income
-
Annuals > 1 > income Statement > net Income
-
Annuals > 1 > income Statement > eps
-
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
-
Annuals > 1 > income Statement > income Tax Expense
2000
Annuals > 1 > income Statement > EBITDA
-
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-
Annuals > 1 > income Statement > currency_symbol
EUR
Annuals > 1 > balance Sheet > cash
-
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
4295000
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
53363000
Annuals > 1 > balance Sheet > property Plant Equipment
2549000
Annuals > 1 > balance Sheet > total Assets
-
Annuals > 1 > balance Sheet > payables
11561000
Annuals > 1 > balance Sheet > short Term Debt
-
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
22242000
Annuals > 1 > balance Sheet > equity
-
Annuals > 1 > balance Sheet > currency_symbol
EUR
Annuals > 1 > cash Flow > net Income
-28600000
Annuals > 1 > cash Flow > depreciation
928000
Annuals > 1 > cash Flow > change In Working Capital
-
Annuals > 1 > cash Flow > cash From Operations
-17139000
Annuals > 1 > cash Flow > capital Expenditures
32000
Annuals > 1 > cash Flow > cash From Investing
-16000
Annuals > 1 > cash Flow > cash From Financing
23739000
Annuals > 1 > cash Flow > net Change In Cash
6345000
Annuals > 1 > cash Flow > currency_symbol
EUR
Annuals > 1 > ratios > PE
-
Annuals > 1 > ratios > PB
-
Annuals > 1 > ratios > ROE
-
Annuals > 1 > ratios > ROA
-
Annuals > 1 > ratios > FCF
-17171000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
45
Annuals > 2 > quarter
2020-12-31
Annuals > 2 > income Statement > revenue
-
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
-
Annuals > 2 > income Statement > operating Expenses
-
Annuals > 2 > income Statement > operating Income
-
Annuals > 2 > income Statement > interest Expense
0
Annuals > 2 > income Statement > pretax Income
-
Annuals > 2 > income Statement > net Income
-
Annuals > 2 > income Statement > eps
-
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
-
Annuals > 2 > income Statement > income Tax Expense
2000
Annuals > 2 > income Statement > EBITDA
-
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
-
Annuals > 2 > income Statement > currency_symbol
EUR
Annuals > 2 > balance Sheet > cash
-
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
3264000
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
43759000
Annuals > 2 > balance Sheet > property Plant Equipment
3154000
Annuals > 2 > balance Sheet > total Assets
-
Annuals > 2 > balance Sheet > payables
7588000
Annuals > 2 > balance Sheet > short Term Debt
-
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
17123000
Annuals > 2 > balance Sheet > equity
-
Annuals > 2 > balance Sheet > currency_symbol
EUR
Annuals > 2 > cash Flow > net Income
-34000000
Annuals > 2 > cash Flow > depreciation
926000
Annuals > 2 > cash Flow > change In Working Capital
-
Annuals > 2 > cash Flow > cash From Operations
-15044000
Annuals > 2 > cash Flow > capital Expenditures
6000
Annuals > 2 > cash Flow > cash From Investing
-376000
Annuals > 2 > cash Flow > cash From Financing
33859000
Annuals > 2 > cash Flow > net Change In Cash
18693000
Annuals > 2 > cash Flow > currency_symbol
EUR
Annuals > 2 > ratios > PE
-
Annuals > 2 > ratios > PB
-
Annuals > 2 > ratios > ROE
-
Annuals > 2 > ratios > ROA
-
Annuals > 2 > ratios > FCF
-15050000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
45
Annuals > 3 > quarter
2019-12-31
Annuals > 3 > income Statement > revenue
-
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
-
Annuals > 3 > income Statement > operating Expenses
-
Annuals > 3 > income Statement > operating Income
-
Annuals > 3 > income Statement > interest Expense
0
Annuals > 3 > income Statement > pretax Income
-
Annuals > 3 > income Statement > net Income
-
Annuals > 3 > income Statement > eps
-
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
-
Annuals > 3 > income Statement > income Tax Expense
4000
Annuals > 3 > income Statement > EBITDA
-
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
-
Annuals > 3 > income Statement > currency_symbol
EUR
Annuals > 3 > balance Sheet > cash
-
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
6107000
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
27765000
Annuals > 3 > balance Sheet > property Plant Equipment
4228000
Annuals > 3 > balance Sheet > total Assets
-
Annuals > 3 > balance Sheet > payables
7139000
Annuals > 3 > balance Sheet > short Term Debt
-
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
12090000
Annuals > 3 > balance Sheet > equity
-
Annuals > 3 > balance Sheet > currency_symbol
EUR
Annuals > 3 > cash Flow > net Income
-30710000
Annuals > 3 > cash Flow > depreciation
985000
Annuals > 3 > cash Flow > change In Working Capital
-
Annuals > 3 > cash Flow > cash From Operations
-28112000
Annuals > 3 > cash Flow > capital Expenditures
69000
Annuals > 3 > cash Flow > cash From Investing
-102000
Annuals > 3 > cash Flow > cash From Financing
21245000
Annuals > 3 > cash Flow > net Change In Cash
-6991000
Annuals > 3 > cash Flow > currency_symbol
EUR
Annuals > 3 > ratios > PE
-
Annuals > 3 > ratios > PB
-
Annuals > 3 > ratios > ROE
-
Annuals > 3 > ratios > ROA
-
Annuals > 3 > ratios > FCF
-28181000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
45
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > final Score
50
Profitability > verdict
Weak
Risk > final Score
50
Risk > verdict
High
Liquidity > metrics > Current Ratio
1.286080424215643
Liquidity > metrics > Quick Ratio
1.286080424215643
Liquidity > final Score
82
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
50
Prev Profitabilities > 1
50
Prev Profitabilities > 2
50
Prev Risks > 0
50
Prev Risks > 1
50
Prev Risks > 2
50
Prev Liquidities > 0
82
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:58:53.802Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-01-21
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa and dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. It has license agreements with Sorbonne Université, CNRS, Inserm and SATT Lutech; Inserm Transfert S.A, Genethon, and Harvard; Massachusetts Institute of Technology; Novartis Pharma AG; Sorbonne University, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale and Satt Lutech; Association Française contre les Myopathies, Inserm Transfert S.A; and non-exclusive license agreement with Adverum Biotechnologies. The company was incorporated in 2012 and is headquartered in Paris, France.
Stock Price
€0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AMast Energy shares advance on UK datatcentre power strategy Proactive Investors
Read more →(Last Updated 2023-06-30)
Health Score
* Institutions hold a combined 0.00% of the total shares of GenSight Biologics S.A.
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-12-31
EPS Actual
—
EPS Estimate
—
EPS Difference
0
Surprise Percent
0%
(Last Updated 2023-06-30)
(Last Updated 2023-06-30)
Revenue
€ 0
Cost Of Revenue
€ 0
Gross Profit
€ 0
Operating Expenses
€ 0
Operating Income
€ 0
Interest Expense
€ 0
Pretax Income
€ 0
Net Income
€ 0
Income Tax Expense
€ 0
EBITDA
€ 0
Total Other Income Expense Net
€ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2023-06-30)
Cash
€ 0
Short Term Investments
€ 0
Receivables
€ 0
Inventories
€ 0
Total Current Assets
€ 0
Property Plant Equipment
€ 0
Total Assets
€ 0
Payables
€ 0
Short Term Debt
€ 0
Long Term Debt
€ 0
Total Liabilities
€ 0
Equity
€ 0
(Last Updated 2023-06-30)
Net Income
€ 0
Depreciation
€ 0
Change In Working Capital
€ 0
Cash From Operations
€ 0
Capital Expenditures
€ 0
Cash From Investing
€ 0
Cash From Financing
€ 0
Net Change In Cash
€ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.